Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be between the ages of 18 and 80, inclusive
Subject must have a diagnosis of prosthetic joint infection (PJI) in a hip or knee joint which has never previously been totally revised because of an infection and for which they are anticipated to undergo a two-stage replacement surgery
Subject must have a positive microbiological identifier of staphylococci.
If Subject is female of childbearing potential, must be willing to practice reliable birth control
You may not be if
Subject has permanent intravascular prosthetic material such as heart valves or pacemakers
Subject has a creatinine clearance (CLCR) \<30 mL/min as determined by the Cockcroft-Gault equation using actual body weight.
Subject has significant hepatic dysfunction
Subject has a fungal or mycobacterial PJI
Subject is known to be HIV-infected with CD4 count ≤ 200 cells/ mm3
Subject has an abnormal creatine phosphokinase (CPK) (elevated CPK level ≥ 2x ULN) at baseline as measured by central laboratory
Subject is currently under treatment with chemotherapeutic agents excluding chronic maintenance therapy (e.g. tamoxifen to prevent relapse of primary breast cancer)
Subject is pregnant, nursing, or lactating.
Subject is receiving or is expected to receive chronic immunosuppressive therapy during the study.
Clareo Health | Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
